ADX-71441
 | |
| Names | |
|---|---|
| IUPAC name N-[5-[4-[(4-chloro-3-fluorophenyl)methyl]-6-methoxy-3,5-dioxo-1,2,4-triazin-2-yl]-2-fluorophenyl]acetamide | |
| Identifiers | |
3D model (JSmol) | |
PubChem CID | |
| |
| |
| Properties | |
| C19H15ClF2N4O4 | |
| Molar mass | 436.80 g·mol−1 |
Except where otherwise noted, data are given for materials in their standard state (at 25 °C [77 °F], 100 kPa). | |
ADX-71441 is a GABAB receptor positive allosteric modulator currently being investigated as a potential treatment for anxiety, epilepsy, pain and other conditions.
Therapeutic potential
[edit]Addiction
[edit]ADX-71441 has been shown to reduce alcohol consumption.[1] This result was observed in both alcohol dependent and non-dependent animals.[2][3]
There were also trials about nicotine addiction, which showed positive results: ADX-71441 was able to decrease some withdrawal symptoms of nicotine withdrawal.[4]
Anxiety
[edit]This compound has also been shown to reduce anxiety in people with PTSD.[5]
Pain
[edit]Experiments have shown that this compound was able to decrease hypersensitivity to pain in mice, Guinea pigs and rats.[5]
Tolerance
[edit]ADX-71441 has been shown to have less tolerance and side effects than direct GABAB agonists, such as baclofen.[2]
References
[edit]- ^ "Addex Reports ADX71441 Reduces Alcohol Intake in a Preclinical Model of Chronic Alcohol Dependence". Addex therapeutics. Retrieved 2024-02-03.
- ^ a b Augier E, Dulman RS, Damadzic R, Pilling A, Hamilton JP, Heilig M (August 2017). "The GABAB Positive Allosteric Modulator ADX71441 Attenuates Alcohol Self-Administration and Relapse to Alcohol Seeking in Rats". Neuropsychopharmacology. 42 (9): 1789–1799. doi:10.1038/npp.2017.53. PMC 5520784. PMID 28294133.
- ^ Colombo G (March 2024). "Positive allosteric modulators of the GABAB receptor: a new class of ligands with therapeutic potential for alcohol use disorder". Alcohol and Alcoholism. 59 (3). Oxford, Oxfordshire. doi:10.1093/alcalc/agae018. PMID 38566580.
- ^ "Addex ADX71441 Positive Results in Preclinical Model of Nicotine Addiction". Addex therapeutics. Retrieved 2024-02-03.
- ^ a b Kalinichev M, Girard F, Haddouk H, Rouillier M, Riguet E, Royer-Urios I, et al. (March 2017). "The drug candidate, ADX71441, is a novel, potent and selective positive allosteric modulator of the GABAB receptor with a potential for treatment of anxiety, pain and spasticity". Neuropharmacology. 114: 34–47. doi:10.1016/j.neuropharm.2016.11.016. PMID 27889489. S2CID 36606154.